2026-07-06 · insulin, basal insulin, glargine, degludec, type 2 diabetes, GLP-1, SGLT2 inhibitors · 19 min read

Why does insulin cause weight gain in type 2 diabetes?

Three mechanisms, not one. Nauck 2003 (Diabetes Care) identified the physiology: as A1c falls, urinary glucose loss — which can reach 200 to 300 kcal/day at a pre-treatment A1c of 9 or 10 — drops to near zero, and those recaptured calories are stored as fat. Skyler 2010 documented the second driver: defensive snacking against hypoglycaemia, either preemptively out of fear or reactively to symptoms. Purnell 2013 (Journal of Clinical Endocrinology and Metabolism) documented the third with DXA — insulin's core metabolic action activates lipoprotein lipase and inhibits lipolysis preferentially in visceral and truncal fat depots, so the weight gained is not evenly distributed. Landmark trials quantified the sum: UKPDS 33 1998 (Lancet) reported roughly 4 kg additional weight gain in the insulin arms over 10 years, ORIGIN 2012 (New England Journal of Medicine) reported 1.6 kg additional at 6 years on insulin glargine, and Riddle 2003 (Diabetes Care) reported 2.6 kg at 24 weeks on the basal-plus-oral template.

Is insulin still first-line for type 2 diabetes?

No, and it has not been for most adults for several years. The ADA 2024 Standards of Care Section 9 order treatment as metformin first, GLP-1 receptor agonist or SGLT2 inhibitor second (or first when atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease is present), dual oral therapy third, and insulin third or fourth line — reserved for adults with severe hyperglycaemia at diagnosis, symptomatic hyperglycaemia, catabolic features, advanced insulin-deficient disease, or failure of the earlier ordering. The Davies 2022 ADA/EASD Consensus Report on Management of Hyperglycaemia in Type 2 Diabetes formalised this modern framework. Insulin remains essential — the disease of insulin insufficiency and resistance still eventually needs replacement therapy in a subset of patients — but it is not the correct first response to modest A1c drift on metformin in an adult who has never tried a GLP-1 or SGLT2 inhibitor.

How much weight will I gain on basal insulin?

The typical range in randomised trials is 2 to 4 kg per year, with larger gains at higher doses, higher baseline A1c (more glucosuria to recapture), and on basal-bolus rather than basal-only regimens. Riddle 2003 Treat-to-Target (Diabetes Care) reported 2.6 kg at 24 weeks on glargine plus oral agents versus 1.9 kg on NPH. ORIGIN 2012 (New England Journal of Medicine), the largest and longest trial, reported 1.6 kg additional weight gain on insulin glargine versus standard care at 6 years — the slow-drift signal. UKPDS 33 1998 reported roughly 4 kg additional at 10 years in the insulin-based intensive arms. DEVOTE 2017 (NEJM) reported about 2 kg over 2 years on degludec or glargine U100. Adults on premixed insulins usually gain more than adults on pure basal, adults on basal-bolus more than basal-only, and adults with the highest starting A1c gain more early because more calories are being recaptured from urine.

Can a GLP-1 or SGLT2 inhibitor prevent insulin-related weight gain?

Yes, and this is the modern layering strategy. DiMeglio 2018 and multiple GLP-1 add-on trials show that adding a GLP-1 receptor agonist to basal insulin usually reduces total daily insulin dose by 20 to 40 percent and neutralises or reverses the weight-gain trajectory. iGlarLixi (Soliqua) and IDegLira (Xultophy) — fixed-ratio combinations of basal insulin and a GLP-1 — deliver a typically weight-neutral or modestly weight-negative net effect. SGLT2 inhibitors layered on basal insulin add modest A1c improvement, roughly 2 kg additional weight loss, and cardiorenal benefits insulin does not provide. Nauck 2007 (Annals of Internal Medicine) put the head-to-head in stark terms: exenatide added to metformin plus a sulfonylurea produced 2.3 kg of weight loss while glargine added to the same background produced 1.8 kg of weight gain — with comparable A1c reduction. If insulin is genuinely needed, layering it on top of metformin, a GLP-1, and an SGLT2 inhibitor rather than starting insulin alone prevents most of the trade-off.

Can I stop insulin after starting a GLP-1 like Wegovy or Zepbound?

Sometimes yes, often you can reduce the dose substantially, and this should never be a self-directed decision. Many adults on insulin were escalated in a pre-GLP-1 era, and a modern re-evaluation with semaglutide, tirzepatide, liraglutide, or dulaglutide layered on can produce a 20 to 40 percent basal insulin dose reduction within 12 weeks, with a subset able to discontinue insulin entirely. The prescriber will typically hold the current basal dose while the GLP-1 is titrated, then reduce basal by 10 to 20 percent every one to two weeks as fasting glucose targets and continuous glucose monitor (CGM) time-in-range hold. Watch for symptomatic hypoglycaemia — the most common signal that basal is now too high — and remember that the GLP-1 improves post-prandial glucose more than fasting glucose, so basal may need proportionately larger cuts than prandial. Do not discontinue insulin without a plan; abrupt withdrawal in an insulin-deficient adult can precipitate hyperglycaemia and, rarely, diabetic ketoacidosis.

What are the sick-day rules for insulin?

Do not stop basal insulin. The single most common serious error during an acute illness in a person with type 2 diabetes on insulin is stopping the basal because appetite has dropped — hepatic glucose production continues during illness, and stopping basal risks hyperglycaemia and, rarely, ketoacidosis. The standard sick-day rules from the ADA/EASD framework are: continue basal insulin at the usual dose; check blood glucose every 3 to 4 hours; check ketones (urine or blood) if glucose exceeds 240 mg/dL or if unwell; hydrate with sugar-free fluids if glucose is high or sugar-containing fluids if glucose is low; adjust prandial insulin to actual intake, not scheduled amounts; and call the prescriber for persistent vomiting, ketones, glucose above 300 mg/dL despite corrections, or any confusion, chest pain, or breathing difficulty. If you are also on an SGLT2 inhibitor, hold it during acute illness — the DKA risk is elevated.

Is insulin safe in pregnancy and gestational diabetes?

Yes — insulin is the pharmacotherapy with the most pregnancy safety data and is the treatment of choice when nutritional therapy alone is not enough. Human insulin, insulin aspart, and insulin lispro carry the longest safety records in pregnancy; NPH, detemir, and (increasingly) glargine are also used. The ADA and ACOG position insulin as first-line pharmacotherapy for gestational diabetes and for pre-existing type 2 diabetes during pregnancy. Metformin is used in some pregnancies but crosses the placenta and has long-term offspring data that are less complete than insulin's. GLP-1 receptor agonists and SGLT2 inhibitors are not recommended in pregnancy — the reproductive-toxicity and human-pregnancy data are limited, and both drug classes should be discontinued when pregnancy is planned or confirmed, with insulin substituted. Weight gain on insulin during pregnancy is expected and appropriate; the priority is glycaemic targets, not weight.

Should I switch from glargine to degludec to gain less weight?

Weight is not usually the reason to switch. DEVOTE 2017 (New England Journal of Medicine) — the head-to-head of degludec versus glargine U100 in 7,637 adults with T2D and cardiovascular risk — showed non-inferior MACE and 40 percent fewer severe hypoglycaemic events on degludec, with weight gain similar in the two arms (about 2 kg over 2 years). BRIGHT 2018 (Diabetes, Obesity and Metabolism) compared glargine U300 to degludec head-to-head and reported roughly 1.5 kg weight gain in both arms over 24 weeks. The clinically relevant differences are the hypoglycaemia margin — degludec and glargine U300 both give slightly more room for aggressive fasting-glucose titration without nocturnal hypoglycaemia — and, in some formularies, cost. If nocturnal hypoglycaemia is limiting your ability to titrate to target, or if you are experiencing hypoglycaemia-defensive snacking, switching to degludec or glargine U300 can indirectly reduce weight-gain drivers even though the head-to-head weight numbers are similar.

Should I be on insulin at all?

This is a legitimate question in 2026, and the honest answer for many long-term insulin users is that a modern re-evaluation is worth the appointment. Millions of US adults were started on basal insulin before GLP-1 receptor agonists and SGLT2 inhibitors reshaped the T2D ordering, and many of them are on insulin doses that would be lower — or unnecessary — with metformin, a GLP-1, and an SGLT2 inhibitor layered on. The re-evaluation is not adversarial to insulin. A subset of adults with advanced insulin-deficient T2D genuinely need insulin, and pregnancy is a specific setting where insulin is preferred. But the case for staying on insulin at the current dose should be affirmatively made by the prescriber and the current metabolic picture, not simply inherited from a decision made 10 years ago. Bring a recent A1c, weight trajectory, CGM report if available, and a list of current medications to the visit and ask directly.

Insulin Therapy and Weight in Type 2 Diabetes: Why Basal Insulin Causes Weight Gain and How to Mitigate It

Insulin is the oldest, most physiologic, and — in advanced disease — the most reliable glucose-lowering drug in type 2 diabetes. It is also the T2D drug that causes the most weight gain: typically 2 to 4 kg per year on basal therapy, disproportionately visceral, through a combination of urinary glucose recapture, defensive snacking against hypoglycaemia, and direct anabolic action on adipose tissue (Nauck 2003, Diabetes Care; Purnell 2013, Journal of Clinical Endocrinology and Metabolism). The landmark trials quantified the sum: UKPDS 33 1998 (Lancet) reported roughly 4 kg additional weight in the insulin-based intensive arms over 10 years, ORIGIN 2012 (NEJM) reported 1.6 kg additional on insulin glargine over 6 years, and Riddle 2003 Treat-to-Target (Diabetes Care) reported 2.6 kg on glargine plus oral agents at 24 weeks.

The honest picture is that insulin remains an essential drug — T2D is a disease of insulin insufficiency and resistance, and a subset of patients will need replacement therapy throughout care — but the ADA 2024 Standards of Care Section 9 has pushed insulin to third or fourth line behind metformin, GLP-1 receptor agonists, and SGLT2 inhibitors, precisely because those newer drugs match insulin’s glycaemic effect without the weight-gain trade-off and, in the case of GLP-1s and SGLT2 inhibitors, come with cardiovascular and renal outcome benefits that insulin has never demonstrated (Marso 2016 LEADER; Buse 2019 REWIND; Zinman 2015 EMPA-REG). When insulin is genuinely needed, layering it on top of metformin, a GLP-1, and an SGLT2 inhibitor — rather than starting insulin as monotherapy — prevents most of the weight-gain trade-off (Nauck 2007, Annals of Internal Medicine; Diamant 2010 LEAD-5, Lancet; DiMeglio 2018). This guide covers who benefits, how insulin drives weight gain, the modern layering strategy, insulin-plus-GLP-1 fixed-ratio combinations, sick-day rules, pregnancy, and de-escalation.

Quick stats

• Basal insulin weight gain: typically +2 to +4 kg per year in adults with T2D, disproportionately visceral (Nauck 2003; Purnell 2013).
• ORIGIN 2012 (NEJM): +1.6 kg additional weight gain on insulin glargine vs standard care at 6 years in 12,537 adults with dysglycaemia and CV risk — and no MACE benefit.
• UKPDS 33 1998 (Lancet): intensive glucose control including insulin arms produced roughly +4 kg additional weight vs conventional therapy over 10 years, alongside a 25% reduction in microvascular complications.
• ADA 2024 Standards of Care Section 9: insulin is third or fourth line for most T2D adults — after metformin, then GLP-1 or SGLT2 inhibitor, then dual oral therapy.
• GLP-1 vs insulin head-to-head (Nauck 2007, Annals of Internal Medicine): exenatide arm lost 2.3 kg while glargine arm gained 1.8 kg with comparable A1c reduction.
• 911 red flag: severe hypoglycaemia with confusion, seizure, or unresponsiveness — call 911, give glucagon nasal spray or intramuscular glucagon if trained.

How insulin fits into the modern T2D ordering

The ADA 2024 Standards of Care Section 9 and the Davies 2022 ADA/EASD Consensus Report on management of hyperglycaemia in T2D describe an ordering that has moved insulin off the front line for most adults.

Why insulin causes weight gain

Four mechanistic threads describe the weight signal — three biological drivers and one framing correction.

1. Recapture of urinary calorie loss

Nauck 2003 (Diabetes Care) laid out the primary physiology. In untreated T2D with A1c of 9 or 10, blood glucose routinely exceeds the renal reabsorption threshold and urinary glucose loss can reach 200 to 300 kcal per day. As insulin lowers A1c to target, glucosuria falls to near zero and those recaptured calories are stored as fat. This driver is largest early in therapy, largest at the highest starting A1c, and explains why the initial weight gain on insulin is roughly proportional to the size of the A1c drop.

2. Defensive snacking against hypoglycaemia

Skyler 2010 documented the second driver. Hypoglycaemia itself drives hunger — the physiologic response to low blood glucose includes rapid appetite escalation — and the fear of hypoglycaemia drives preemptive snacking. Both behaviours add calories that would not otherwise have been eaten. DEVOTE 2017 (NEJM) — the trial that established insulin degludec’s 40% reduction in severe hypoglycaemia versus glargine U100 — matters here not just for the hypoglycaemia numbers but because reducing hypoglycaemia reduces the defensive-eating driver. The ADA/EASD 2018 Hypoglycaemia Consensus codified the classification and management of hypoglycaemia; the sub-clinical driver of weight gain is the daily practice patient behaviour around avoiding it.

3. Direct anabolic effect on adipose tissue

Purnell 2013 (Journal of Clinical Endocrinology and Metabolism) used DXA to demonstrate the third driver: insulin’s core metabolic action includes activation of lipoprotein lipase and inhibition of lipolysis, preferentially in visceral and truncal depots. The weight gained on insulin is not evenly distributed — the DXA data showed disproportionate visceral and truncal fat accumulation, which is the fat distribution most associated with cardiometabolic risk. This is why the modern framing insists that insulin-driven weight gain is not “just” 3 kg — it is 3 kg in the worst possible place.

4. What insulin is not

Insulin is not a first-line T2D drug in the modern ordering. It is not the correct first response to modest A1c drift on metformin. It is not a substitute for a GLP-1 or SGLT2 inhibitor unless those drugs are contraindicated, unavailable, or have been tried and failed. And it is not the target of an anti-insulin argument — advanced insulin-deficient T2D genuinely needs replacement therapy, pregnancy is a specific setting where insulin is preferred, and inpatient hyperglycaemia is nearly always managed with insulin. The framing this article is defending is use insulin when it is genuinely needed, layer it appropriately, and de-escalate when the modern combination allows it.

Insulin category primer

The insulin category is organised by pharmacokinetics — how fast the drug is absorbed and how long it lasts — rather than by chemistry. The relevant categories for T2D adults are basal (long-acting), prandial (rapid- or short-acting mealtime), premixed (a fixed combination of the two), ultra-rapid (a faster prandial subcategory), and inhaled.

Time-course and dose-response

Weight gain on insulin is largest early — when A1c is dropping the most and urinary calorie recapture is maximal — then plateaus over several months and drifts slowly for years afterward. The dose-response scales roughly with total daily insulin dose and with the number of prandial injections.

5-step protocol for minimising weight gain on insulin

This is the practical rhythm most endocrinologists follow in 2026. It is faithful to ADA 2024, the Davies 2022 ADA/EASD consensus, and the ADA/EASD 2018 hypoglycaemia framework.

Step 1: Layer, do not substitute

Continue metformin unless there is a specific reason to stop (eGFR below 30, severe GI intolerance, symptomatic B12 deficiency). Add or continue a GLP-1 receptor agonist — semaglutide, tirzepatide, liraglutide, or dulaglutide — before or alongside insulin whenever the patient qualifies and can access one. Add or continue an SGLT2 inhibitor — empagliflozin, dapagliflozin, canagliflozin — when heart failure, chronic kidney disease, or established ASCVD is present. Every layer reduces the insulin dose required and, with it, the weight-gain driver. Bailey 2019 (NEJM) documented that continuing metformin alongside insulin preserves a 2 to 3 kg advantage over insulin monotherapy.

Step 2: Choose the right basal

DEVOTE 2017 and BRIGHT 2018 are the two head-to-heads that matter. Insulin degludec and glargine U300 both offer a slightly wider hypoglycaemia margin than glargine U100 or NPH, particularly at night — which indirectly reduces the defensive-snacking driver of weight gain even when the head-to-head weight numbers are similar. For a T2D adult starting basal insulin in 2026, degludec or glargine U300 is the modal first choice. Avoid pre-mixed insulins as first-line for weight-conscious patients — the premixed formulations typically drive the largest weight gain in the category.

Step 3: Titrate to fasting glucose target, not by fear

The ADA 2024 fasting glucose target for most non-pregnant T2D adults is 80 to 130 mg/dL. Undertitrating — leaving basal too low because of hypoglycaemia fear — causes ongoing hyperglycaemia and glucotoxicity, which paradoxically worsens insulin resistance and requires more insulin over time. Overtitrating — pushing basal past target — causes hypoglycaemia, which drives defensive snacking and weight gain. The correct approach is a structured titration algorithm (many prescribers use +2 units every 3 days until fasting is 80 to 130 mg/dL, held for any glucose below 80).

Step 4: Reassess prandial insulin need

Basal alone is often insufficient in later T2D, and post-prandial glucose becomes the limiting factor for A1c. Before adding scheduled prandial injections, consider GLP-1-augmentation first — GLP-1 receptor agonists improve post-prandial glucose substantially, and adding a GLP-1 rather than prandial insulin usually delivers similar A1c improvement with less weight gain and less hypoglycaemia. Basal-bolus is the correct answer when the GLP-1 has been tried and post-prandial glucose still exceeds target, or when a GLP-1 is contraindicated.

Step 5: Set a weight-and-CGM co-monitor

A 5 to 10% baseline weight rise on insulin should trigger a treatment review — not because the insulin has failed, but because the current combination is not the right one. On CGM, time-below-range under 4% is the practical hypoglycaemia signal; more than that means the basal or prandial dose is too high and defensive snacking is likely driving weight. Adults not on CGM should self-monitor fasting glucose most mornings and log symptomatic lows.

Insulin vs other T2D drugs

Basal insulin + GLP-1 combination

The single biggest lever for insulin-related weight gain is combining basal insulin with a GLP-1 receptor agonist. Nauck 2007 (Annals of Internal Medicine) reported the head-to-head that framed the modern combination: exenatide added to metformin plus a sulfonylurea produced 2.3 kg of weight loss while glargine added to the same background produced 1.8 kg of weight gain, with comparable A1c reduction. Diamant 2010 LEAD-5 (Lancet) reported liraglutide 1.8 mg plus metformin plus sulfonylurea at −1.8 kg versus glargine at +1.6 kg at 26 weeks. DiMeglio 2018 documented that GLP-1 add-on to basal insulin reduces total daily insulin dose by 20 to 40% and prevents further weight gain.

The clinical form this takes in 2026 is either a free combination (basal insulin as one injection, GLP-1 as a separate injection or oral semaglutide) or a fixed-ratio combination — iGlarLixi (Soliqua) combining glargine U100 with lixisenatide, and IDegLira (Xultophy) combining degludec with liraglutide. Both fixed-ratio products deliver typically weight-neutral or modestly weight-negative net effects in T2D and simplify the injection burden.

Basal insulin + SGLT2 inhibitor

Layering an SGLT2 inhibitor on top of basal insulin is additive on A1c, produces a modest weight-neutral to weight-negative shift, and adds the cardiorenal outcome benefits that insulin does not provide. The specific caution is diabetic ketoacidosis — DKA on SGLT2 inhibitors is rare in T2D but does occur, and the risk is elevated at very low carbohydrate intake, during acute illness, and in the perioperative period. The practical rule is to hold the SGLT2 inhibitor during sick days, before elective surgery, and during any period of very restricted carbohydrate intake; the basal insulin continues.

Insulin in T2D with chronic kidney disease

Kidney disease alters insulin pharmacokinetics — insulin is partially cleared by the kidney, so lower eGFR extends its half-life and increases hypoglycaemia risk. In T2D with CKD, favour degludec or glargine U300 for the slightly wider hypoglycaemia margin, adjust prandial doses down as eGFR declines, and use CGM aggressively to detect nocturnal lows. SGLT2 inhibitors remain indicated (and often first-line) down to eGFR of 20, and GLP-1 receptor agonists are safe throughout the CKD range with modest dose adjustments in the most advanced disease. See our companion coverage of the SGLT2 inhibitors and weight framework for cardiorenal layering.

Insulin during acute illness — sick-day rules

The single most common serious error in an adult on insulin during an acute illness is stopping the basal because appetite has dropped. Hepatic glucose production continues during illness — often accelerated by stress hormones — and stopping basal risks hyperglycaemia and, rarely, ketoacidosis. The standard sick-day pattern is: continue basal at the usual dose, check blood glucose every 3 to 4 hours, check ketones (urine or blood) if glucose exceeds 240 mg/dL or symptoms warrant, hydrate with sugar-free fluids if glucose is high or sugar-containing fluids if glucose is low, adjust prandial insulin to actual intake, and call the prescriber for persistent vomiting, ketones, glucose above 300 mg/dL despite corrections, chest pain, or breathing difficulty. Hold the SGLT2 inhibitor during acute illness; the basal insulin continues.

Insulin de-escalation after starting a GLP-1

For many adults on insulin who start a GLP-1 receptor agonist — Wegovy (semaglutide 2.4 mg), Zepbound (tirzepatide), Mounjaro (tirzepatide), Ozempic (semaglutide 1 or 2 mg) — insulin doses can be reduced substantially. The typical pattern is a 20 to 40% basal reduction within 12 weeks, with a subset of patients able to discontinue insulin entirely. The prescriber will usually hold the current basal while the GLP-1 titrates, then reduce basal by 10 to 20% every one to two weeks as fasting glucose and CGM time-in-range hold. Prandial insulin often needs proportionately larger reductions because the GLP-1 improves post-prandial glucose more than fasting glucose. Watch for symptomatic hypoglycaemia — the most common early signal that basal is now too high. Do not discontinue insulin unilaterally; in advanced insulin-deficient T2D, abrupt withdrawal can precipitate hyperglycaemia and, rarely, DKA. See our overview of tirzepatide weight loss and semaglutide weight loss for the GLP-1 side of the plan.

Insulin in pregnancy — T2D and gestational diabetes

Insulin is the safest pharmacotherapy in pregnancy, and it is the treatment of choice when nutritional therapy is not enough for gestational diabetes or when pre-existing T2D is not controlled on lifestyle alone. Human insulin, insulin aspart, and insulin lispro carry the longest human-pregnancy safety records; NPH, detemir, and (increasingly) glargine are used. GLP-1 receptor agonists and SGLT2 inhibitors are not recommended in pregnancy — the reproductive-toxicity and human-pregnancy data are limited and both classes should be discontinued when pregnancy is planned or confirmed, with insulin substituted. Weight gain on insulin during pregnancy is expected, appropriate, and not the metric to optimise; glycaemic targets take priority. See our companion piece on gestational diabetes and weight loss for the postpartum arc.

The honest question — “Should I be on insulin at all?”

Many T2D adults on insulin in 2026 were started on it in an era before GLP-1 receptor agonists and SGLT2 inhibitors reshaped the ordering. A modern re-evaluation — with metformin at target dose, a GLP-1 receptor agonist added or optimised, an SGLT2 inhibitor added when the cardiorenal indication is present — can produce meaningful insulin dose reductions or, in a subset, discontinuation. The re-evaluation is not adversarial to insulin. UKPDS 80 2008 (NEJM) demonstrated the 10-year post-trial legacy effect of early tight control: the metabolic benefit of good glycaemic control persists even after the specific drug regimen is de-escalated, which is part of why aggressive early control (with or without insulin) matters. But the case for staying on insulin at the current dose should be affirmatively made by the current metabolic picture and the prescriber, not simply inherited from a decision made a decade ago.

Red flags — when to see a doctor or call 911

• Severe hypoglycaemia with confusion, seizure, or unresponsiveness — call 911. Give glucagon nasal spray or intramuscular glucagon if trained and available. This is the highest-priority insulin emergency.
• New abdominal pain plus ketones on SGLT2 inhibitor plus insulin — call 911 for possible euglycemic diabetic ketoacidosis; hold the SGLT2 inhibitor and continue insulin as directed.
• Severe symptomatic hypoglycaemia at night — call the prescriber within 24 hours for a basal dose review; a switch to degludec or glargine U300 or a dose reduction is the typical response.
• Persistent hypoglycaemia despite correction — recheck insulin dose calculation, ask about hepatic or renal function changes, review new medications; call the prescriber the same day.
• New severe polyuria, polydipsia, or unintentional weight loss — signals worsening hyperglycaemia or insulin under-dosing; call the prescriber the same day.
• Accidental over-ingestion or pediatric access — call 1-800-222-1222 (US Poison Control) for immediate guidance.

Bottom line

Insulin is essential in advanced insulin-deficient T2D, in pregnancy, and in inpatient hyperglycaemia — and it causes 2 to 4 kg of weight gain per year on basal therapy, disproportionately visceral, through urinary glucose recapture, defensive snacking against hypoglycaemia, and direct anabolic action on adipose tissue. The ADA 2024 Standards of Care order metformin first, GLP-1 or SGLT2 inhibitor next, and insulin third or fourth line — precisely because the newer classes match insulin’s glycaemic effect without the weight trade-off and add cardiovascular and renal benefits insulin has never demonstrated. When insulin is needed, layering it on top of metformin, a GLP-1, and (where indicated) an SGLT2 inhibitor prevents most of the weight-gain trade-off. For adults on long-standing insulin who have never tried a modern GLP-1 or SGLT2 inhibitor, a re-evaluation with the current formulary is worth the appointment.

How this connects to the rest of the site

For the diagnostic and lifestyle context, see diabetes and weight loss, prediabetes and weight loss, type 1 diabetes and weight loss, and gestational diabetes and weight loss. For the mechanism-level story, see insulin resistance and weight loss and metabolic syndrome and weight loss. For the reproductive-endocrine context, see PCOS and weight loss. For the drug-class layering, see metformin and weight, SGLT2 inhibitors and weight, semaglutide weight loss, tirzepatide weight loss, Ozempic for weight loss, Wegovy weight loss, Zepbound weight loss, Saxenda weight loss, and weight loss drug safety.